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Abstract
Introduction—Approximately 10-15% of women reportedly take an antihistamine during 
pregnancy for the relief of nausea and vomiting, allergy and asthma symptoms, or indigestion. 
Antihistamines include histamine H1-receptor and H2-receptor antagonists.
Areas covered—This is a systematic evaluation of the peer-reviewed epidemiologic literature 
published through February 2014 on the association between prenatal exposure to antihistamines 
and birth defects. Papers addressing histamine H1- or H2-receptor antagonists are included. Papers 
addressing pyridoxine plus doxylamine (Bendectin in the United States, Debendox in the United 
Kingdom, Diclectin in Canada, Lenotan and Merbental in other countries) prior to the year 2001 
were excluded post-hoc because of several previously published meta-analyses and commentaries 
on this medication.
Expert opinion—The literature on the safety of antihistamine use during pregnancy with respect 
to birth defects is generally reassuring though the positive findings from a few large studies 
warrant corroboration in other populations. The findings in the literature are considered in light of 
three critical methodological issues: (1) selection of appropriate study population; (2) 
ascertainment of antihistamine exposures; and (3) ascertainment of birth defects outcomes. 
Selected antihistamines have been very well-studied (e.g. loratadine); others, especially H2- 
receptor antagonists, require additional study before an assessment of safety with respect to birth 
defects risk could be made.
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Introduction
Antihistamines, available in both prescription and over-the-counter formulations, are 
commonly used during early pregnancy for the treatment of nausea and vomiting, symptoms 
of asthma and allergies, and relief of indigestion1, 2. Collectively, antihistamine use is 
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reported by 10-15% of pregnant women 2, 3; a recent analysis of pooled data from two large 
national studies showed that several individual antihistamine components (i.e. promethazine, 
diphenhydramine, loratadine, cetirizine, doxylamine, chlorpheniramine, and fexofenadine) 
are each used by 1-4% of pregnant women during the first trimester 1. First generation H1-
receptor antagonists (e.g. diphenhydramine [Benadryl®], dimenhydrinate [Dramamine], 
doxylamine plus pyridoxine (vitamin B6) [Bendectin in the United States, Debendox in the 
United Kingdom, Diclectin in Canada, Lenotan and Merbental in other countries] can cross 
the blood-brain barrier with resulting sedative and anticholinergic side effects and are 
frequently used to treat allergic reactions and nausea and vomiting of pregnancy (NVP). 
Second generation H1-receptor antagonists (e.g. loratadine [Claritin], cetirizine [Zyrtec], 
fexofenadine [Allegra]) lack those side effects and are primarily used to treat symptoms of 
asthma and allergies. H2-receptor antagonists (e.g. ranitidine [Zantac], cimetidine 
[Tagamet], famotidine [Pepcid], nizatidine [Axid]) used to treat indigestion, are less 
commonly used during pregnancy, though recent data indicate that approximately 1 in 100 
pregnant women take ranitidine during the first trimester 1.
The most controversial antihistamine ever in widespread use in the United States, the 
combination of doxylamine plus pyridoxine (originally a three-component drug which also 
included dicyclomine [an antispasmodic]), was reformulated to the more commonly-used 
two-component version in 1976 after a double-blind evaluation demonstrated that 
dicyclomine did not contribute to the drug's effectiveness (reported in Brent, 2003) 4. Sold in 
the United States from 1957-1983, an estimated 30-35% of pregnant women used 
doxylamine plus pyridoxine for the treatment of NVP during the height of its popularity the 
1970s 4. However, because of concerns about fetal safety, doxylamine plus pyridoxine has 
been the topic of at least 27 original research peer-reviewed publications 5, three published 
meta-analyses 5-7, and at least 30 commentaries, editorials, and letters to the editor (4, 8-11 ). 
The meta-analysis by McKeigue and colleagues based on 16 cohort and 11 case-control 
studies reported a pooled relative risk showing no association between any birth defect and 
first trimester exposure to doxylamine plus pyridoxine (0.95; 95% confidence interval (CI) 
0.88-1.04). Separate analyses were conducted on types of birth defects including neural tube 
defects, oral clefts, congenital heart defects (CHD), and limb reductions, with relative risks 
ranging from 0.81 to 1.12, all of which had confidence intervals that contained the null value 
of 1.0 5. However in the face of numerous lawsuits stating that the drug caused birth defects, 
including a class action case with over 1,000 plaintiffs, 4 its manufacturer stopped marketing 
doxylamine plus pyridoxine in the United States in 1983. As of April 2013, however, the US 
Food and Drug Administration has granted approval for a marketing a formulation of 
doxylamine plus pyridoxine for the treatment of NVP in women who do not respond to 
conservative management.
This review evaluates the peer-reviewed epidemiologic literature on the association between 
prenatal exposure to antihistamine medications and birth defects. It is limited in scope to 
only structural birth defects; other potential adverse pregnancy outcomes such as fetal loss, 
preterm delivery, or low birth weight, or longer-term neurodevelopmental outcomes, are not 
included in this review. Papers addressing either histamine H1- or H2-receptor antagonists 
(or both antihistamine subtypes) are included. The findings in the literature are considered in 
light of three critical methodological issues: (1) selection of appropriate study population; 
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(2) ascertainment of antihistamine exposures; and (3) ascertainment of birth defects 
outcomes.
Methods
2.1 Data sources and search terms
The authors conducted a search of the peer-reviewed literature using PubMed (National 
Center for Biotechnology Information, United States National Library of Medicine) with a 
filter for human studies in the English language published through February 4, 2014. Two 
distinct search strings were used, the results of which were combined and de-duplicated in a 
single EndNote X7 (Thomson Reuters, 1998-2013) library:
(1) antihistamines AND (pregnancy OR birth defects OR congenital defects OR 
congenital malformations)
(2) (nausea OR vomiting) AND (pregnancy OR birth defects OR congenital defects 
OR congenital malformations)
Search string (2) was used to ensure that papers which had a primary focus on NVP, but 
reported analyses for antihistamine use were captured. Papers that only reported on the 
associations with NVP did not meet inclusion criteria and would be excluded. Two co-
authors each initially screened one-half of the article titles and abstracts for relevance; two 
additional coauthors then independently re-screened the article titles and abstracts. If both 
co-authors who reviewed a title and/or abstract agreed that the article could be excluded, 
then it was excluded without further review. If one of the two co-authors determined that the 
screened title and/or abstract needed a review of the full text, either because it appeared to 
meet inclusion criteria or it could not be determined whether it met inclusion criteria, the full 
text was retrieved and reviewed. The reference lists of the selected articles were also 
searched for additional papers that were not ascertained through the PubMed search (see 
flowchart, Figure 1). Through personal communication with the author, one additional 
article that was electronically published in September, 2013 but was not indexed in PubMed 
until March 2014 was also included in the review (in flowchart box entitled “Articles 
identified through other sources”).
2.2 Inclusion criteria
A study was included in this review if it:
(1) was written in English,
(2) was based on human data,
(3) reported the results of original research (excluded case reports, case series, 
editorials [without original data], commentaries [without original data], review 
papers, clinical guideline documents, and duplicate reports),
(4) reported on exposure during pregnancy to histamine H1-receptor (first or second 
generation) and/or H2-receptor antagonists at a clinically appropriate dose (i.e. 
excluded one study that investigated fetal effects of maternal suicide attempts 
through promethazine overdose) and an etiologically relevant time period for 
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birth defects (i.e. studies of antihistamine exposure administered during labor 
and delivery to prevent nausea were excluded),
(5) reported structural birth defects (collectively or as individual subtypes) as an 
outcome, and
(6) included a comparison population (e.g. comparison of the prevalence of birth 
defects among antihistamine exposed and unexposed pregnancies in a cohort 
design or comparison of prevalence of antihistamine exposure among mothers of 
infants born with birth defects and mothers of infants born without birth defects 
[or with a different birth defect other than the birth defect of interest] in a case-
control design).
Studies that focused exclusively on doxylamine plus pyridoxine use and were published 
during the 1980s and 1990s (through the year 2000) were excluded post-hoc, as it was 
determined that re-reviewing this literature was unnecessary in light of the several 
previously published meta-analyses and commentaries on this medication. In addition, if 
other studies included doxylamine plus pyridoxine as one of several antihistamines under 
investigation, the results of the other antihistamines are included in this review and the 
doxylamine plus pyridoxine results are not discussed, though the table notes for Tables 1 
and 2 indicate the papers with published results for doxylamine plus pyridoxine use. Recent 
papers (since January 2001) that included doxylamine plus pyridoxine exposures are 
abstracted and included in this review because these are subsequent to the last published 
meta-analysis.
Included studies were not required to report a measure of association (i.e. odds ratio, 
prevalence ratio, risk ratio) or the results of statistical testing. For selected studies in which 
adequate data were available but a measure of association was not reported in the original 
publication, we calculated a measure of association. When distinct publications included 
overlapping data, it was noted in the text and notes for Tables 1 and 2.
3. Results
Out of the 7,670 articles identified through PubMed and 45 identified through other sources, 
54 papers met the inclusion criteria for this review (Figure 1). Thirty-one are cohort studies 
(Table 1); 23 are case-control studies (Table 2).
3.1 Histamine H1-receptor antagonists: Findings from cohort studies
A total of 24 cohort studies reported findings with respect to histamine H1-receptor 
antagonists (Table 1). Eight of these 24 cohort studies were based on data from a Teratogen 
Information Service (TIS). Briefly, TIS locations in the United States and in several 
countries provide evidence-based information to mothers, health care professionals, and the 
general public about medications and other exposures during pregnancy and while 
breastfeeding. This typically occurs when physicians or women call the service concerned 
about a chemical or medication exposure. During the call, information on pregnancy 
exposures is collected. For TIS conducting studies of pregnancy outcomes, within a year of 
delivery, a follow-up survey is sent to the women to gather information on the outcome of 
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the pregnancy. In some services, the outcome of the pregnancy is verified with a health care 
provider. Additional data sources are sometimes linked to the information gathered during 
the initial telephone call or in the follow-up interview. Many of the studies using TIS data 
derive an “unexposed” group from women calling about exposures deemed to be “non-
teratogenic”, such as dental examinations, x-ray exposures, and use of medications such as 
acetaminophen.
One cohort study analyzed antihistamines in the aggregate only 12 though reported 
frequencies of selected birth defects by specific medication exposures. Källén explored a 
wide array of first and second generation H1-receptor antagonists in relation to several 
pregnancy outcomes, but reported estimates of association by indication only (not specific 
antihistamines), and analyzed medications used to treat NVP separately from those used to 
treat allergies. Among the reported analyses of aggregated outcomes such as all birth 
defects, selected birth defects, all CHDs, specified CHDs, and all birth defects except CHDs, 
there were no significantly elevated associations with either antihistamines used to treat 
NVP or those used to treat allergies 12.
3.1.1 First generation H1-receptor antagonists
3.1.1.1 Cyclizine or meclizine: Seven cohort studies investigated the association between 
cyclizine or meclizine exposure and birth defects 13-19. A Northern California Kaiser 
Permanente cohort study of 4,277 pregnancies between 1960-1964 included detailed 
maternal interviews to ascertain medication use in addition to validation from the prenatal 
record 18. There were 315 pregnancies exposed to meclizine or cyclizine in the first 
trimester compared with 3,902 unexposed to any antinauseant medication. The prevalence of 
birth defects was comparable in the two groups (3.2% in the meclizine/cyclizine group and 
3.8% in the unexposed comparison group) 18. In a follow-up study of the same population 
including several additional years of data, Milkovich and van den Berg found no difference 
in the prevalence of birth defects among women exposed to meclizine or cyclizine compared 
with a group of women with unmedicated NVP 16.
Based on data from over 25,000 pregnancies in Sydney, Australia from 1956-1961, McBride 
reported a prevalence of cleft palate of 4.4 per 1,000 among 1,125 women who took 
cyclizine during pregnancy, compared with a baseline prevalence of 0.78 per 1,000 among 
24,208 unexposed pregnancies. However, in a sub-analysis comparing the cyclizine-exposed 
group to a group with untreated NVP (i.e. controlling for indication), the difference in the 
two groups was no longer noteworthy (4.4 per 1,000 compared with 3.6 per 1,000) 15.
Using data from the United States Collaborative Perinatal Project (CPP), Shapiro and 
colleagues 17 analyzed data for 1,014 pregnant women who took meclizine in the first four 
lunar months of pregnancy compared with 49,268 unexposed pregnancies. A wide array of 
birth defects were investigated; eye and ear defects were the only significant associations 
identified (standardized relative risk: 2.79; 95% CI: 1.12-5.73). However, further 
investigation of subtypes of eye and ear defects did not reveal a relationship between 
meclizine and any specific birth defect 17.
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Three analyses of Swedish data explored meclizine in relation to birth defects 13, 14, 19. The 
earliest included 5,753 women, 778 of whom used an antiemetic (i.e. promethazine, 
prochlorperazine [an antiemetic with no antihistaminic properties], diphenhydramine, or 
meclizine) during pregnancy. Meclizine exposure was not associated with an increased risk 
of any of the birth defects under study 14. In a more recent analysis of Swedish surveillance 
data that focused only on meclizine, the frequency of birth defects was 3.2% among 16,536 
meclizine exposed pregnancies; the association was slightly protective (odds ratio (OR): 
0.91; 95% CI: 0.83-0.99) when compared with an unexposed group 19. Lastly, in a 2005 
study by Asker and colleagues, there was no reported association between birth defects and 
cyclizine, and again a protective effect was noted for meclizine (cyclizine OR: 1.08; 95% 
CI: 0.86-1.35; meclizine OR: 0.89; 95% CI 0.82-0.96). In this Swedish population, 
meclizine was the most commonly used antihistamine (there were over 18,000 meclizine-
exposed pregnancies compared with less than 2,000 pregnancies exposed to any other 
antihistamine) 13.
3.1.1.2 Doxylamine plus pyridoxine: Two relatively recent papers have investigated 
doxylamine plus pyridoxine20, 21. Using data obtained from the Canadian TIS (the 
“Motherisk Program”) from 2001-2003, Boskovic and colleagues compared women with no 
NVP with two groups of women with NVP – the first group of women took a standard dose 
of doxylamine plus pyridoxine and the second group took a “supradose”. Among the group 
without NVP, there were no birth defects reported; the frequency of birth defects was 2/122 
(1.6%) among the women on the standard dose and 0/124 among women on the 
supradose 21. Askenazi-Hoffnung and colleagues compared doxylamine plus pyridoxine to 
metoclopramide for the treatment of NVP using data from an Israel TIS. There were no birth 
defects among the 29 women exposed to doxylamine plus pyridoxine and one among the 29 
women exposed to metoclopramide 20.
3.1.1.3 Hydroxyzine: There were two cohort studies that examined the association between 
hydroxyzine exposure and birth defects 22, 23. In a 1971 study conducted in Turkey, 
hydroxyzine (n=100) or placebo (n=50) was administered during the first two months of 
pregnancy 23. Among the 150 pregnancies enrolled, 115 had information on fetal outcomes. 
There was one birth defect in the hydroxyzine group; and none in the placebo group. 
Hydroxyzine was also investigated by Einarson and colleagues using data from Motherisk 
Program 22. Among 43 women with first trimester hydroxyzine exposure, 2 infants were 
born with major birth defects; in the comparison population of 120 women exposed to non-
teratogens, there were none.
3.1.1.4 Other first generation H1-receptor antagonists – brompheniramine, 
chlorpheniramine, dimenhydrinate, diphenhydramine, promethazine, triprolidine: In a 
matched analysis using data from a German population based cohort study from 1964-1976, 
the association between first trimester use of “miscellaneous antiemetics” (including 
meclizine, dimenhydrinate, and chlopheniramine) and birth defects was 0.92 (90% CI: 
0.42-2.00) based on 11 birth defects among 628 exposed pregnancies and 12 birth defects 
among 628 unexposed pregnancies 24.
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Two analyses of data from the Seattle-based Group Health Cooperative of Puget Sound 
analyzed a wide range of first trimester antihistamine use in relation to risk for birth 
defects 25, 26. Based on data from 1977-1979, Jick and colleagues compared the prevalence 
of birth defects among women exposed to selected antihistamines in the first trimester of 
pregnancy to a baseline risk of birth defects of 11.7 per 1,000. The prevalence among those 
exposed to triprolidine (6/384; 15.6 per 1,000) and diphenhydramine (1/361; 2.8 per 1,000) 
were not statistically significantly different from the baseline 26. In an update of this analysis 
using data from 1980-1982, Aselton and colleagues reported a baseline birth defects 
prevalence of 16.1 per 1,000. Among women with first trimester exposures to 
diphenhydramine, triprolidine, chlorpheniramine, brompheniramine or promethazine, the 
prevalence of birth defects was not statistically significantly different from the baseline 25. 
Schatz and colleagues, using data from the Kaiser-Permanente Prospective Study of Asthma 
During Pregnancy, reported a prevalence of birth defects of 5.5% among unexposed 
pregnancies and 3.7% among pregnancies exposed to chlorpheniramine, tripelennamine, or 
other antihistamines (not otherwise specified) in the first trimester 27.
Bsat and colleagues published a prospective evaluation of three outpatient regimens for 
NVP: promethazine, prochlorperazine (an antiemetic with no antihistaminic properties), and 
pyridoxine plus metoclopramide. There were no birth defects noted among the 52 women 
exposed to promethazine; one birth defect was reported among the women exposed to 
prochlorperazine 28.
Kullander and Kallen's analysis of a Swedish prospective cohort found no association 
between first trimester exposure to diphenhydramine and birth defects. The one association 
reported in that paper was between promethazine exposure and congenital dysplasia of the 
hip (based on 11 observed cases; 4 were expected) 14. Asker and colleagues’ later analysis 
of Swedish surveillance data found no association with promethazine (OR: 0.91; 95% CI: 
0.75-1.11)13.
3.1.2 Second generation H1-receptor antagonists—Eight cohort studies in this 
review investigated the association between one or more second generation H1-receptor 
antagonists and birth defects 22, 29-35
3.1.2.1 Cetirizine: Two cohort studies have investigated the association between cetirizine 
use during pregnancy and birth defects 22, 35. Einarson and colleagues, using data from the 
Motherisk Program, observed no pregnancies affected by a major birth defect among the 33 
exposed to cetirizine in the first trimester 22; no birth defects were reported in the non-
teratogen comparison group as well. An analysis of the Berlin TIS data documented three 
pregnancies affected by birth defects among the 177 exposed to cetirizine in the first 
trimester (1.7%) compared with 24/1,521 (1.6%) in the non-teratogen comparison group 
(OR: 1.07; 95% CI: 0.21-3.59) 35.
3.1.2.2 Loratadine: Four cohort studies have investigated the association between 
loratadine use during pregnancy and birth defects 29-31, 33. The first investigation to report 
an association between loratadine and hypospadias was by Källén and Olausson using data 
from the Swedish Medical Birth Registry 30. In a cohort of over 540,000 women with 
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deliveries from 1995-2001, 2,780 infants were exposed to loratadine in early pregnancy. The 
observed prevalence of hypospadias was 5.4 per 1,000 among the loratadine-exposed 
pregnancies, significantly higher than the expected prevalence of 1 in 500 (OR: 2.27; 95% 
CI: 1.33-3.87) 30. Five years later, after linkage with additional national registries, the same 
authors published a follow-up study and proposed that the 2001 “signal” had been a chance 
finding. In the revised analysis, which included three additional years of data (2002-2004), 
the prevalence of hypospadias among the loratadine-exposed pregnancies was 1.04 per 
1,000 during 2002-2004, dramatically lower than during 1995-2001. When analyzing the 
full time period, the association was attenuated from what had been previously published 
(RR: 1.61; 95% CI: 1.04-2.34) 31. Two papers published in 2003 based on TIS data also 
investigated the fetal safety of loratadine 29, 33. Using data form the Israel TIS, Diav-Citrin 
and colleagues reported one birth defect among 126 first trimester loratadine-exposed 
pregnancies (0.8%), compared with 7/146 (4.8%) pregnancies exposed to “other 
antihistamines”, and 25/844 (3.0%) pregnancies exposed to non-teratogens. Moretti and 
colleagues pooled data across four TIS (Canada [Motherisk], Israel, Italy, Brazil) in their 
analysis of loratadine use and birth defects. Among those exposed to loratadine, 5/143 
(3.5%) had a major birth defect, compared with 6/150 (4.0%) in the comparison group of 
women exposed to non-teratogens; these prevalence estimates were not significantly 
different 33.
3.1.2.3 Terfenadine and astemizole: Three cohort studies, all based on TIS data, 
investigated terfenadine and/or astemizole use during pregnancy in relation to birth 
defects 29, 32, 34. Using data from the Motherisk Program and the Italy TIS, Loebstein and 
colleagues reported no cases of birth defects among 65 women with first trimester exposure 
to terfenadine compared with 2 birth defects among 111 exposed to a non-teratogen (RR: 
0.57; 95% CI: 0.06-5.39) 32. A second analysis from the Motherisk Program (in 
collaboration with the Pregnancy Healthline in Philadelphia) focused on astemizole. 34. 
Among 114 women exposed to astemizole there were 2 reported cases of major birth defects 
(1.8%); there were 2 reported among the 114 women in the non-teratogen comparison group 
as well 34. Although not the primary exposure of interest in a study by Diav-Citrin and 
colleagues using Israel TIS data (exposure of interest was loratadine, see above), the authors 
reported the prevalence of major birth defects for specific antihistamines included in their 
“other antihistamines” analytic group. The frequencies of birth defects among women 
exposed to astemizole (3/50; 6%) or terfenadine (2/27; 7.4%) during pregnancy were not 
significantly different from the comparison group 29.
3.2 Histamine H1-receptor antagonists: Findings from case-control studies
A total of 21 case-control studies that met inclusion criteria for this review reported findings 
with respect to histamine H1-receptor antagonists (Table 2). Four studies analyzed 
antihistamines in the aggregate only 36-39, the remainder reported aggregated analyses in 
addition to analyses of specific antihistamines.
In a paper focused on risk factors for infant craniostenosis (more commonly referred to as 
craniosynostosis), Källén and Robert-Gnansia 36 compared prenatal use of medications 
among the mothers of 398 infants born with craniostenosis between 1995-2002 with the 
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nearly 730,000 Swedish births during the same time period. Twenty-two case mothers had 
documentation in their prenatal record of first trimester exposure to an antihistamine 
compared with an expected frequency of 15.6 based on the larger population data (observed/
expected ratio: 1.4; 95% CI: 0.9-2.1).
Two manuscripts based on data from the Slone Epidemiology Center Birth Defects Study 
(Slone BDS) also known as the Pregnancy Health Interview Study 37, 38 reported on the 
associations between any antihistamine use and gastroschisis; the more recent paper also 
reported on the association with small intestinal atresias 38. In data from 1976-1990, there 
were 76 gastroschisis cases, among whom 10 (13.2%) were exposed to antihistamines 
(excluding antiemetics) and 2,142 controls affected by other, non-related birth defects, 
among whom 173 (8.1%) were exposed to antihistamines leading to an adjusted OR of 1.3 
(95% CI: 0.5-3.1) 37; in more recent Slone BDS data (1995-1999) based on 206 
gastroschisis cases, the association was closer to the null (OR: 0.6; 95% CI: 0.3-1.2). There 
was also no association with small intestinal atresia (OR: 0.9; 95% CI: 0.4-1.8) (based on 
126 small intestinal atresia cases) 38.
Boneva and colleagues, using data from metropolitan Atlanta from 1982-1983, analyzed 
antihistamine use for the treatment of severe first trimester NVP among 998 mothers of 
infants with a CHD and 3,029 mothers of infants born without any major birth defect. The 
analysis focused on Bendectin use (not reported in this review) and antihistamines in 
general. Comparing women with the most severe level of NVP to those with no NVP, the 
association between CHD and using any antinausea medication was protective with a 
relative risk estimate of 0.74 (95% CI: 0.56-0.97). Considering specific CHD subtypes, all 
associations among women with NVP, comparing those who took medications with those 
who did not, were below the null (but not statistically significant), with the exception of 
tetralogy of Fallot, which was greater than 1.0 (OR: 2.19; 95% CI: 0.39-22.32), based on 8 
cases, 6 of whom took medication to treat NVP, compared with 2 who did not take 
medication 39.
3.2.1. First generation H1-receptor antagonists
3.2.1.1 Antihistamines other than doxylamine plus pyridoxine: The authors of 1982 and 
1984 reports on the association between doxylamine plus pyridoxine exposure and pyloric 
stenosis 40, 41 re-analyzed their data to explore the role of antihistamines excluding 
doxylamine plus pyridoxine antihistamines, and reported findings in letters to the editor in 
1985 42, 43. Based on data from the mothers of 71 cases with pyloric stenosis (5 exposed) 
and 3,002 control mothers (40 exposed), Eskenazi and Bracken reported a 5-fold increase in 
risk (OR: 5.61; 95% CI: 2.14-14.67) for use of antihistamines excluding doxylamine plus 
pyridoxine 41. Aselton and Jick, using the Puget Sound Group Health Cooperative data from 
the mothers of 12 cases of pyloric stenosis and 32 matched control mothers, reported an 
elevated but not statistically significant association (matched OR: 4.1; 95% CI: 0.8-21.7).
3.2.2.2 Other first generation H1-receptor antagonists: The oldest case-control study 
included in this review was a letter to the editor published in The Lancet in 1961 reporting 
on the frequency of first trimester use of meclizine, dimenhydrinate, and cyclizine among 
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mothers of 266 infants with birth defects, and mothers of two groups of control infants 
(n=266 in each control group) 44. Considering the three antihistamines combined, there were 
no differences across the three groups in the prevalence of medication use (11.3% of cases; 
11.7% of control group 1; 12.0% of control group 2). A 1973 report using data from 
1964-1972 from the Finnish Register of Congenital Malformations 45 investigated whether 
exposure to a combination drug, imipramine (a tricyclic antidepressant) plus chloropyramine 
(an antihistamine) was more common among mothers of 2,784 birth defect cases than 
among mothers of 2,784 matched controls. Three case mothers were exposed to imipramine/
chloropyramine; no control mothers were exposed. The following year Saxén, in a letter to 
the editor of The Lancet, reported on the association between antihistamine intake and oral 
clefts (cleft palate only [CPO], cleft lip with or without cleft palate [CL/P]), using data from 
the Finnish Register. There was no association between cyclizine use and oral clefts, yet 
there was a significant difference between the frequency of diphenhydramine use among 
mothers of CPO cases (8/232; 3.4%) and mothers of controls (6/590; 1.0%) 46. Concern 
about oral clefts continued; in 1983, Golding and colleagues reported on data from the 
United Kingdom based on 196 oral cleft cases and 407 matched controls. Exposure to 
several antihistamines during the first 69 days of pregnancy was considered; only 
promethazine (and doxylamine plus pyridoxine) had a sufficient prevalence of exposure for 
analysis. The frequency of promethazine use was not significantly different among mothers 
of oral clefts cases and controls 47.
In 1971, Nelson and Forfar reported on a Scottish case-control study with 175 cases with 
major defects, 283 cases with minor defects, and 911 controls in which mothers were 
interviewed before hospital discharge about medication use during pregnancy. An attempt 
was made to validate maternal report of medication use by following up with the pharmacy 
that filled the prescription. Two of the 175 (1.1%) case mothers were exposed to an 
antihistamine (i.e. promethazine, diphenhydramine, triprolidine, mepyramine, 
diphenylpyraline, chlorpheniramine, chlorcyclizine, and trimeprazine) during the first 
trimester; 26 of the 911 (2.9%) control mothers were exposed and no individual 
antihistamine was more commonly used in the first trimester among case mothers than 
control mothers 48.
The Hungarian Case Control Surveillance of Congenital Anomalies (HCCSCA) has been 
used to examine the risks associated with several antihistamines. The HCCSCA uses 
national birth defects surveillance data, the Hungarian Congenital Abnormality Registry 
(HCAR). Notification of cases with birth defects to HCAR is mandatory for physicians in 
Hungary; cases among live births, fetal deaths or terminations of pregnancy are reported. 
Medication data for cases and controls were gathered in one of two ways: (1) prenatal care 
“logbooks” and other medical records (gathered prospectively); or (2) responses to maternal 
questionnaires (self-reported, gathered retrospectively). In an investigation of 23 subtypes of 
major birth defects, dimenhydrinate was found to be inversely associated with risk for 
obstructive defects of the urinary tract (prevalence ratio (PR): 0.2; 95% CI: 0.1-0.7)49. In a 
similarly structured analysis, medically recorded promethazine use (excluding promethazine 
use that was only self-reported by mothers and not validated with documentation of use in 
the medial record) in the first trimester of pregnancy was also inversely associated with 
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obstructive urinary tract defects, as well as hypospadias, undescended testes, clubfoot, and 
the aggregation of all defects in the analysis (OR: 0.8; 95% CI: 0.7-0.9) 50. In a 2003 paper, 
Czeizel and colleagues 51 limited their analysis of the association between oral clefts and 
antihistamine exposure to women with hyperemesis gravidarum, a severe form of NVP often 
resulting in hospitalization 52. They found no association between dimenhydrinate use and 
CL/P (OR: 1.20; 95% CI: 0.66-2.19) but a positive association between the medication and 
CPO (OR: 2.47; 95% CI: 1.10-5.54). The prevalence of dimenhydrinate use among mothers 
of two oral cleft subtypes was substantially different, with 25-30% of CL/P case and control 
mothers reporting use of the medication, but nearly 50% of the mothers of CPO cases 
reporting use 51.
Using data from the National Birth Defects Prevention Study (NBDPS), Gilboa and 
colleagues3 and Anderka and colleagues53 conducted analyses of the association between 
first trimester antihistamine use and selected birth defects. Gilboa and colleagues, using data 
from 1997-2003, conducted frequentist and Bayesian analyses of the association between 
self-reported first trimester use of 10 specific first generation antihistamines (i.e. clemastine, 
dimenhydrinate, diphenhydramine, doxylamine, hydroxyzine, meclizine, pheniramines 
[chlorpheniramine and brompheniramine], promethazine, triprolidine, and antihistamine 
“not otherwise specified”) or any antihistamine, and 26 isolated major birth defects 3. Three 
second generation antihistamines were also investigated (i.e. cetirizine, fexofenadine, and 
loratadine) (see below in Second generation H1-receptor antagonists). Only one association 
had a magnitude greater than 3.0 – the association between prenatal meclizine exposure and 
cleft palate (Bayesian posterior OR: 6.2; 95% Posterior Interval: 1.8-21.3) – based on 5 
exposed cases and 4 exposed controls. The authors identified several modest, but elevated 
associations with diphenhydramine, and doxylamine. Many of these were not previously 
identified in the literature and could represent chance findings. The authors conducted 
several sensitivity analyses to explore the robustness of these findings to residual 
confounding by indication, but the results were largely unchanged.
Anderka and colleagues’ analysis focused on the subpopulation of mothers of cases and 
controls with NVP, and four birth defect subtypes - CL/P, CPO, neural tube defects (NTD), 
and hypospadias using data from 1997-2004. Among NBDPS controls, the prevalence of 
NVP was nearly 70%; among those with NVP, approximately 15% reported treatment. The 
associations between NVP itself and the four birth defect subtypes included in the analyses 
were either protective or null, with OR estimates ranging from 0.84 to 1.00. The reported 
associations with antihistamine antiemetics (including promethazine as an itemized 
subgroup) and the other antihistamines (including diphenhydramine, cetirizine, and 
doxylamine as itemized subgroups) ranged from 0.9 to 1.4, all with confidence intervals 
including the null value of 1.0. The only exception was an elevated, but not statistically 
significant OR of the association between NTD and doxylamine plus pyridoxine of 1.84 
(95% CI: 0.71-4.78).
In the most recent paper included in this review, Li and colleagues, using data from the 
Slone Birth Defects Study (BDS) (gastroschisis cases overlapped somewhat with those 
analyzed by Werler and colleagues38), divided their study into a priori (hypothesis testing) 
and exploratory (hypothesis generating) analyses 54. The 16 a priori analyses, selected based 
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on previous reports in the literature, were: loratadine and hypospadias (see below in Second 
generation H1-receptor antagonists); diphenhydramine and CPO, CL/P, NTD, spina bifida, 
limb reduction defects, and gastroschisis; chlorpheniramine and eye defects, ear defects, 
spina bifida, and CL/P; and doxylamine and oral clefts, pyloric stenosis, hypoplastic left 
heart syndrome, spina bifida, and NTD. None of the a priori analyses demonstrated a 
significantly elevated association. In their exploratory analyses, there were a few elevated 
associations: diphenhydramine and transposition of the great arteries (OR: 2.3; 95% CI: 
1.1-5.0), right ventricular outflow tract obstruction defects (OR: 1.6; 95% CI: 1.0-2.7), renal 
collecting system anomalies (OR: 1.5; 95% CI: 1.0-2.2); chlorpheniramine and NTD (OR: 
2.6; 95% CI: 1.1-6.1), tetralogy of Fallot (OR: 3.1; 95% CI: 1.2-8.4), hypoplastic left heart 
syndrome (OR: 4.9; 95% CI: 1.6-14.9) and anomalies of the great veins (OR: 3.3; 95% CI: 
1.1-10.0); and doxylamine and renal collecting system anomalies (OR: 2.7; 95% CI: 
1.3-5.6) 54. These were all novel associations, and like the novel associations reported by 
Gilboa and colleagues, could represent chance findings and are in need of replication in 
other datasets.
3.2.3 Second generation H1-receptor antagonists—Gilboa and colleagues published 
the only case-control study investigating exposure to cetirizine and fexofenadine; there were 
no elevated associations observed for either antihistamine 3. Loratadine, however has been 
much more thoroughly studied, and has been of particular interest in the literature, in part 
due to the 2002 Swedish study (discussed above) that suggested an association with 
hypospadias 12. Several case-control studies have since explored this association – one using 
data from the Slone BDS 54, two using data from the NBDPS 3, 55, and three using data from 
Denmark 56-58. Li and colleagues considered the hypospadias – loratadine association as one 
of their a priori hypotheses (based on previous suggestions in the literature). Based on self-
reported medication use data from the mothers of 632 cases with hypospadias and 3,448 
mothers of controls, there was no association found between first trimester loratadine use 
and hypospadias (OR: 0.8; 95% CI: 0.4-1.7) 54. Li and colleagues investigated the 
association between loratadine and 20 other major birth defects in their “exploratory” 
analyses; all of the adjusted OR were between 0.5 and 1.7 with 95% confidence intervals all 
including the null value of 1.0 54. A 2004 Morbidity and Mortality Weekly Report reported 
the results of an NBDPS analysis of maternal loratadine use from one month before 
pregnancy through the end of the first trimester among 563 male infants with 2nd or 3rd 
degree hypospadias (cases with first degree hypospadias are excluded from the NBDPS) and 
1,444 male control infants 55. The analysis also included a larger group of nonsedating 
antihistamines (which included loratadine) and sedating antihistamines (not otherwise 
specified). All associations with hypospadias were null; loratadine OR: 0.96; 95% CI: 
0.41-2.22, nonsedating antihistamines OR: 0.95; 95% CI: 0.48-1.89, sedating antihistamines 
OR: 1.02; 95% CI: 0.68-1.53 55. Gilboa and colleagues, using two additional years of data 
from NBDPS and exploring a wide array of birth defects, did not observe an elevated risk 
with loratadine for hypospadias or any other major birth defect, with the exception of 
transverse limb deficiencies (OR: 2.16; 95% CI: 1.08-4.30) 3. Two reports from Denmark 
published in 2006 reported on analyses of the association between first trimester loratadine 
use and hypospadias using case-control data57, 58. One was based on data from four Danish 
counties where 227 cases of hypospadias and 10 matched controls per case (n=2,270) were 
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identified using linked national hospital discharge and birth registry datasets from 
1989-2002. Medication use during pregnancy was identified through further linkage with 
pharmacy records. One case and eight control mothers were exposed to loratadine in the 
period from 30 days before conception through the end of the first trimester; there was no 
elevated risk of hypospadias associated with this exposure (OR: 1.4; 95% CI: 0.0-10.5) 58. 
The second Danish report was based on a case-control study nested within the Danish 
National Birth Cohort, in which 203 cases of hypospadias and 2,030 matched controls were 
identified. During maternal interview, one case and 25 control mothers self-reported use of 
loratadine from one month before pregnancy through the end of the first trimester. Similar to 
the results from the record-linkage based analysis, there was no association with 
hypospadias (OR: 0.9; 95% CI: 0.1-6.9) 57. Lastly, in 2008, in a nationwide record-linkage 
analysis using data from 1996-2004, 1,575 cases of hypospadias were identified, 7 (0.4%) of 
whom had prenatal loratadine exposure. Among 14,660 matched controls, 88 (0.6%) were 
exposed to loratadine. No association was observed (prevalence ratio [PR]: 0.6; 95% CI: 
0.3-1.4) 56.
3.3 Histamine H2-receptor antagonists: Findings from cohort and case-control studies
The body of literature investigating the association between histamine H2-receptor 
antagonists and birth defects is substantially smaller than that for H1-receptor antagonists, 
with seven cohort studies 59-65 and three case-control studies 53, 66, 67 meeting inclusion 
criteria for this review. Colin Jones and colleagues reported on 12-month post-marketing 
surveillance in Scotland of 9,809 users of cimetidine and a comparison population of 9,140 
non-users. Over the surveillance, there were 20 pregnancies exposed to cimetidine and 22 
unexposed pregnancies; among cimetidine users there was one birth defect reported – a case 
of Down syndrome. There were no birth defects among the non-users 59.
Two studies used data from a TIS – the first based on data from the Motherisk Program 62 
and the second based on pooled data from 18 members of the European Network of 
Teratogen Information Service (ENTIS) 60. In the analysis of Motherisk data, there were 
185 pregnancies exposed to histamine H2-receptor antagonists (i.e. ranitidine [the most 
common], cimetidine, famotidine, nizatidine), 142 of them were first trimester exposed and 
resulted in a live birth. Three birth defects occurred among these pregnancies (2.1%) 
compared with 5 birth defects among 143 pregnancies in the comparison group (3.5%). The 
difference between the prevalence of birth defects among these two groups was not 
statistically significant (p=0.55) 62. The analysis of pooled ENTIS data (n=553 exposed to 
H2-receptor antagonists; n=1,390 in comparison group exposed to “non-teratogenic” 
substances) had similar findings with a prevalence of birth defects of 2.7% among the 
exposed pregnancies and 3.5% among those unexposed to H2-receptor antagonists 60. In 
another analysis of the Motherisk data (combined with data from Italy and France TIS), first 
trimester exposure to H2-receptor antagonists (not otherwise specified; n=113; n=98 with 
live births) was compared with exposure to non-teratogens (n=113; n=66 with live births) 65. 
The prevalence of birth defects among those with live births was similar in the exposed and 
unexposed groups: H2-receptor antagonists: 3.1%; non-teratogens: 3.0%.
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In a 1998 publication of data from the Swedish Medical Birth Registry, Källén reported on 
the association between acid-suppressing drugs (e.g. proton pump inhibitors, H2-receptor 
antagonists) and birth defects. The baseline birth defects prevalence was 3.9%; among users 
of H -receptor antagonists, the prevalence was 2.4% (6/255) (OR: 0.46; 95% CI: 
0.17-1.20)61 Ruigómez and colleagues reported on two cohorts of cimetidine- and 
ranitidine-exposed pregnancies – one from Italy and one from the United Kingdom 64. In the 
United Kingdom cohort, prevalence of birth defects among cimetidine-exposed pregnancies 
was 4.0% (9/227) and among ranitidine-exposed pregnancies was 7.4% (17/229), compared 
with the baseline prevalence of 5.7% among the unexposed population. In the Italy cohort, 
2/10 (20%) cimetidine-exposed pregnancies and 3/101 (3.0%) rantidine-exposed 
pregnancies were compared with the unexposed baseline of 2.9%. Measures of association 
for each medication were calculated from pooled data: cimetidine (RR (95% CI)): 1.3 
(0.7-2.6); ranitidine: 1.5 (0.9-2.6) 64. In the most recently published cohort analysis, Matok 
and colleagues used data from the largest health maintenance organization in Israel to 
examine the safety of H2-receptor antagonists during pregnancy 63. The associations 
between any major birth defect and first trimester exposure to any H2-receptor antagonist 
(n=1,148 exposed pregnancies) or famotidine (n=878 exposed pregnancies) were both null 
(OR: 1.03; 95% CI: 0.80-1.32 for any H2-receptor antagonist and OR: 1.21; 95% CI: 
0.92-1.58 for famotidine). No measure of association was calculated for ranitidine because 
there were fewer than seven birth defects noted (n=276 exposed pregnancies) 63.
Anderka and colleagues, using NBDPS data, reported on H2-receptor antagonists as a group, 
and where sample size permitted, ranitidine. There was no association found between H2-
receptor antagonists and CL/P (OR: 0.57; 95% CI: 0.19-1.67), CPO (OR: 1.04; 95% CI: 
0.39-2.75), or hypospadias (OR: 1.07; 95% CI: 0.41-2.83). There was an elevated, though 
not statistically significant association with NTD (OR: 1.80; 95% CI: 0.80-4.05), though 
when restricted to ranitidine exposure only, the association did not persist (OR: 1.28; 95% 
CI: 0.43-3.82) 53.
Data from the HCCSCA have been used in two recent case control analyses exploring H2-
receptor antagonists and birth defects. In the first study, Ács and colleagues explored the 
association among mothers with severe chronic dyspepsia. Severe chronic dyspepsia 
affected 148 case mothers and 214 control mothers; 9.5% (14/148) case mothers and 12.6% 
(27/214) control mothers took an H2-receptor antagonist (i.e. cimetidine or ranitidine, not 
specified in the paper) (OR: 0.7; 95% CI: 0.4-1.4) 66. In the second study, Bánhidy and 
colleagues, using data from HCCSCA restricted their analyses of the association between 
cimetidine exposure and major birth defects to mothers with definitive peptic ulcer disease 
(PUD). There were 20 mothers of cases (6 exposed) and 58 mothers of matched controls (7 
exposed); the association was elevated (OR: 3.1; 95% CI: 0.9-10.8) 67.
Conclusion
In summary, the majority of findings reported in this body of literature demonstrate a lack of 
association between prenatal antihistamine exposure and birth defects. Among the 31 cohort 
studies included in this review, two identified any statistically significant positive 
associations between antihistamines and birth defects (Table 3). Among the 23 case-control 
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studies included in this review, seven identified any statistically significant positive 
associations (Table 3). Supplemental online tables are provided that detail the frequencies of 
antihistamine exposure – birth defect outcome combinations. Although this lack of reported 
associations is reassuring, and suggests that antihistamines are unlikely to be strong risk 
factors for the major birth defects considered in the literature, a few large studies did 
identify associations that might warrant follow-up and corroboration in other study 
populations 3, 54. Considering the populations included in this review, the vast majority of 
the 54 studies are from the U.S., Canada, or Scandinavia. Given this, there is likely a lack of 
heterogeneity in the reviewed literature with respect to race-ethnicity and population 
diversity. The inclusion criterion of an English-language publication likely contributed to 
this.
It is important to note, however, that these might be chance findings only, given the large 
number of comparisons conducted. The most thoroughly studied “signal” in the recent 
literature, that of the association between loratadine and hypospadias, first identified in data 
from the Swedish Medical Birth Registry 30, has not been confirmed in a subsequent case-
control nor cohort analysis 3, 31, 54-58. This, too, is reassuring and confirms the need for 
continued research using different designs and study populations. However, other 
antihistamines, especially H2-receptor antagonists (e.g. ranitidine, cimetidine, famotidine, 
nizatidine) have much less literature on which an assessment of safety can be based and 
further study to understand the potential fetal effects of H2-receptor antagonists is needed.
Expert Opinion
The findings in this literature should be considered in light of three critical methodological 
issues: (1) selection of appropriate study population; (2) ascertainment of antihistamine 
exposures; and (3) ascertainment of birth defects outcomes.
5.1 Selection of appropriate study population
The distinction between population-based studies and studies based on a convenience 
sample is important. The population-based case-control studies included in this 
review 3, 39, 49, 53, 55, 66, 67 have the advantage of deriving cases from surveillance systems 
that, in general, attempt to capture all major birth defects cases occurring in a population. 
Most of the significant findings were reported in case-control studies which are typically 
better able to assess individual types of birth defects rather than being limited to an 
assessment of all birth defects as an aggregate group. Given the rarity of major birth defects 
in the population (approximately 3% overall 68; specific birth defects are less common) 
population-based cohort studies for birth defects are less frequent in the literature; however, 
cohort studies in both Sweden 14, 19, 30, 31 and the United States 17, 69 have been conducted 
making important contributions to the literature. The Swedish cohorts were built from 
extensive linkages of national registries; while the Collaborative Perinatal Project gathered 
data through maternal interviews of pregnant women enrolled at medical centers around the 
United States 70, 71. Cohorts derived from health maintenance organizations are designed to 
simulate population-based cohorts 18, 25-27, 63 and in some situations do capture the vast 
majority of the population in a given geographic area. These cohorts have access to rich 
clinical information as well as prescription claims. Cohorts based on a convenience sample, 
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however, such as those derived from the TIS around the United States and internationally, 
while likely having acceptable internal validity, have questionable external generalizability. 
The TIS serve a critically important role – providing counsel to concerned women and 
providers about chemical and medication exposures during pregnancy and might provide 
important initial signals of teratogenicity. However, TIS study cohorts are comprised 
exclusively of individuals who choose to inquire about an exposure with a 
TIS 20-22, 29, 32, 33, 35, 60,65. Those who inquire about an exposure are likely to be 
qualitatively different from those who do not; those who do not inquire cannot, by 
definition, be in a TIS cohort. In addition, the TIS studies, by necessity, must select a 
comparison group of women exposed to “something” – since this is the entirety of their 
cohort. The studies tend to choose a comparison group of women exposed to 
“nonteratogenic agents” that is consisting of women exposed to dental x-rays or 
acetaminophen (see Table 2).
5.2 Ascertainment and analysis of antihistamine exposures
A second important issue to consider is the ascertainment and analysis of antihistamine 
exposures. Medication exposure during pregnancy is typically ascertained in one of two 
ways: (1) self-report by the mother, either prospectively or retrospectively and reported 
either in prenatal care records or during a maternal interview for the purposes of the study; 
or (2) linkage with pharmacy records or pharmaceutical claims. Both approaches are 
represented in the 54 papers included in this review though self-report by the mother was the 
most common; over 30 studies used the approach either alone or in combination with one of 
the other approaches. Given that many of the antihistamines of interest are currently sold 
over-the-counter, self-reported exposure assessment is a critical tool. In addition, given 
concerns about the safety of medication use (including antihistamine use) during 
pregnancy 72, it is not uncommon for women to fill a prescription, but decide not to take it 
during pregnancy 73. However, retrospective self-reporting has limitations – the most 
concerning is the potential for biased or inaccurate recall 74. The Slone BDS and NBDPS 
attempt to limit inaccurate recall by asking about specific indications of medications, 
categories of medications, and specific medications, including both generic and brand 
names. Study participants in the BDS are also provided with picture booklets of medications 
as well as a calendar to highlighting key dates and events to aid recall 2, 37, 38, 54. Earlier 
BDS analyses also used a “malformed control” group 2, 37, 38; this design was chosen under 
the assumption that mothers of control infants born with birth defects other than the birth 
defect of interest might have less biased recall than mothers of control infants born without 
any major birth defects. In addition, NBDPS has approximately a 70% response rate among 
cases and controls; analyses have suggested that NBDPS participants are representative of 
the populations from which they were selected 75. However if mothers of cases and controls 
have differential participation with respect to pregnancy exposures, study findings could be 
subject to selection bias.
In the analytic phase of a study, steps can be taken to enhance the accuracy of the exposure 
data. One of the most common approaches in studies of birth defects is to limit the 
medication exposure to the first trimester (sometimes also including the 30 days prior to 
conception to account for the fact that women who are prescribed a medication prior to 
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conception may take it during after conception as well). Since the primary period of 
susceptibility to human teratogens is the first eight weeks of pregnancy (approximately 10 
weeks when counting from the date of last menstrual period) 76, a focus on medication 
exposure during the first trimester (since medication exposure data are often too imprecise to 
accurately focus on specific weeks) is appropriate. While most studies limited the period of 
exposure to the first trimester, a handful explored the association with exposure any time 
during pregnancy 13, 60, potentially leading to an underestimate of the association with birth 
defects. In another analytic approach, the Slone BDS has developed and utilized an exposure 
classification algorithm based on the certainty of recall to help categorize individuals as 
“likely” or “possibly” exposed to a medication 77. Furthermore, the investigators of several 
case-control studies 39, 51, 53, 66, 67 have restricted analyses to individuals with a particular 
indication for medication use (e.g. NVP, peptic ulcer disease and severe dyspepsia in the 
papers noted above) as a method of minimizing confounding by indication 78. This is an 
advantage in this body of literature, especially since a lack of NVP is considered a risk 
factor for a poor pregnancy outcome. In addition, because women often take multiple 
medications during pregnancy79 analyses can exclude women who took medications during 
pregnancy known to be teratogenic or adjust for other medication use.
5.3 Ascertainment of birth defects outcomes
Among the studies included in this review, the data sources for the ascertainment of birth 
defects varied widely with respect to data quality and specificity. In studies using birth 
defects data derived from state or national surveillance programs, the quality and accuracy 
of the data were likely to be high 3, 12, 19, 30, 31, 39, 46, 49, 51, 53, 55-58, 61. In datasets 
developed exclusively through linkages between national birth registry data and hospital 
discharge data with cases of birth defects identified by International Classification of 
Diseases (ICD) coding, the quality might be somewhat lower than data that are actively 
abstracted from medical records, however, the statistical power that comes with larger 
sample sizes as well as the ability to create small, relatively homogeneous categories of birth 
defects is beneficial. Additionally, in some studies 39, 54, 55 rigorous clinical review of every 
case 80-82 was undertaken to verify reported diagnoses and determine whether the case met 
the study's inclusion criteria. Similarly, a few studies in the review are based on data from 
health maintenance organizations 18, 25-27, 42, 63 with medical records forming the 
foundation of the birth defects ascertainment and in some of these studies, additional clinical 
review of potential cases was also undertaken.
In contrast, in other studies, such as those based on the TIS included in this 
review 20-22, 29,32, 33, 35, 60, 65, the pregnancy outcome data were self-reported by mother 
who initially called the TIS, up to a year or more after their initial inquiry. This delay could 
lead to a substantial loss to follow-up, if mothers could not be located in order to report on 
the pregnancy outcome. While the reported pregnancy outcome was verified with the child's 
pediatrician in some of the included studies, this was not universally done across all TIS-
based analyses.
A final methodological issue pertaining to birth defects outcome ascertainment is follow-up 
– the time period after birth during which birth defects could be identified and reported. In 
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most state and national surveillance systems, this period of time is at least one year, 
accounting for the fact that not all birth defects are identified prenatally or immediately after 
birth. Some studies ascertained birth defects over a shorter period of time, for example, at 
delivery 23 or before age 5 months 37, 38, 54. In the BDS, the 5-month cut-off was intentional, 
to help ensure the conduct of maternal interviews no later than 6 months after delivery.
Despite these methodological issues, the body of literature on the risk of birth defects from 
antihistamine use in early pregnancy remains reassuring, particularly for the first generation 
H1-receptor antagonists. There is still a need for larger studies with clinical verification of 
birth defect subtypes, validation of maternal recall of medication exposures, and appropriate 
selection of study populations to follow-up on some of the signals found in previous studies, 
as well as a need to enrich the body of literature on H2-receptor antagonists, which are 
currently relatively understudied.
Finally, as stated earlier, this review was limited in scope to only structural birth defects; 
other potential adverse pregnancy outcomes such as fetal loss, preterm delivery, or low birth 
weight, or longer-term neurodevelopmental outcomes were not included. To have a 
complete understanding of the safety of medication for use during pregnancy, an 
understanding of the full spectrum of adverse outcomes associated with that medication is 
required. At this time the body of literature investigating other adverse pregnancy or 
developmental outcomes associated with prenatal use of antihistamines is much smaller than 
that focused on birth defects.
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• A systematic evaluation was undertaken of the peer-reviewed epidemiologic 
literature published through February 2014 on the association between prenatal 
exposure to antihistamines and birth defects.
• A total of 54 studies met inclusion criteria for the review.
• Among the 31 cohort studies in the review, two identified significant positive 
associations; among the 23 case-control studies, seven identified significant 
positive associations.
• Histamine H1-receptor antagonists have been more thoroughly studied than H2-
receptor antagonists.
• The literature on the safety of antihistamine use during pregnancy with respect 
to birth defects is generally reassuring though the positive findings from a few 
large studies warrant corroboration in other populations.
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